30391-87-8

Usage

Uses

2-Amino-N-(sec-butyl)benzamide is a useful research intermediate for organic synthesis.

InChI:InChI=1/C11H16N2O/c1-3-8(2)13-11(14)9-6-4-5-7-10(9)12/h4-8H,3,12H2,1-2H3,(H,13,14)

Upstream product

• 33966-50-6 SEC-BUTYLAMINE 
• 118-48-9 isatoic anhydride 

Downstream Products

• 838596-29-5 3-[2-(sec-butylcarbamoyl)phenylcarbamoyl]-6-methyl-N-(2,5-dimethylphenyl)benzenesulfonamide 
• 1628027-30-4 C₁₈H₁₉ClN₂O₄S 
• 1628027-29-1 C₁₉H₂₁ClN₂O₄S 
• 1609388-86-4 3-[2-(sec-butylcarbamoyl)phenylcarbamoyl]-N-(2,5-dimethylphenyl)benzenesulfonamide 
• 1609388-87-5 3-[2-(sec-butylcarbamoyl)phenylcarbamoyl]-N-phenylbenzenesulfonamide 
• 1609388-88-6 5-[2-(sec-butylcarbamoyl)phenylcarbamoyl]-2-methyl-N-[(3-benzamido)phenyl]benzenesulfonamide 
• 1609388-90-0 3-[2-(sec-butylcarbamoyl)phenylcarbamoyl]-N-(4-hydroxyphenyl)benzenesulfonamide 
• 1043257-69-7 2-(3-bromobenzamido)-N-(sec-butyl)benzamide 
• 77642-42-3 2-phenyl-3-(1-methylpropyl)-4(3H)-quinazolinone 
• 908505-47-5 2-(3-bromo-4-methylbenzamido)-N-(sec-butyl)benzamide 
• 1319212-72-0 2-[4,6-bis(isobutylamino)-[1,3,5]triazin-2-ylamino]benzoic acid 
• 1319212-74-2 2-(4,6-bis(isobutylamino)-[1,3,5]triazin-2-ylamino)-N-[but-2-yl]-benzamide 
• 1319212-71-9 methyl 2-(4,6-bis(isobutylamino)-[1,3,5]triazin-2-ylamino)benzoate 
• 1319212-73-1 N-(but-2-yl)-2-(4,6-dichloro[1,3,5]triazin-2-ylamino)benzamide 

Relevant academic research and scientific papers

Synthesis and anticancer activity of N -substituted 2-arylquinazolinones bearing trans -stilbene scaffold

A novel series of 2-arylquinazolinones 7a-o bearing trans-stilbene moiety were designed, synthesized, and evaluated against human breast cancer cell lines including human breast adenocarcinoma (MCF-7 and MDA-MB-231) and human ductal breast epithelial tumor (T-47D). Among the tested compounds, the sec-butyl derivative 7h showed the best profile of activity (IC50 5 μM) against all cell lines, being 2-fold more potent than standard drug, etoposide. Our investigation revealed that the cytotoxic activity was significantly affected by N3-alkyl substituents. Furthermore, the morphological analysis by acridine orange/ethidium bromide double staining test and flow cytometry analysis indicated that the prototype compound 7h can induce apoptosis in MCF-7 and MDA-MB-231 cells.

Optimization of small-molecule inhibitors of influenza virus polymerase: From thiophene-3-carboxamide to polyamido scaffolds

Influenza virus infections represent a serious concern to public health, being characterized by high morbidity and significant mortality. To date, compounds targeting the viral ion-channel M2 or the viral neuraminidase are the drugs available for treatment of influenza, but the emergence of drug-resistant viral mutants renders the search for novel targets and their possible inhibitors a major priority. Recently, we demonstrated that the viral RNA-dependent RNA polymerase (RdRP) complex can be an optimal target of protein-protein disruption by small molecules, with thiophene-3-carboxamide derivatives emerging as promising candidates for the development of new anti-influenza drugs with broad-spectrum activity. Here, we report a further dissection of the thiophene-3-carboxamide structure. By using a GRID molecular interaction field (MIF)-based scaffold-hopping approach, more potent and nontoxic polyamido derivatives were identified, highlighting a new space in the chemical variability of RdRP inhibitors. Finally, a possible pharmacophoric model highlighting the key features required for RdRP inhibition is proposed.

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.